| Summary of Cash Payment Due Under Financial Instruments |
Total estimated cash payments due under the financial instruments described in Note 10, “Long-Term Obligations” (excluding the Amended Revenue Interest Agreement as amounts due under this agreement are calculated based on future revenues) are as follows (in thousands):
|
|
|
|
|
|
|
Total Cash Payments |
|
For the three months ended September 30, 2026 |
|
$ |
25,972 |
|
For the three months ended December 31, 2026 |
|
|
14,788 |
|
For the three months ended March 31, 2027 |
|
|
14,507 |
|
For the three months ended June 30, 2027 |
|
|
14,226 |
|
For the twelve months ended June 30, 2027 |
|
$ |
69,493 |
|
|
| Schedule of Revenue and Expense Categories in Single Operating Segment |
The following table presents the significant revenue and expense categories (in thousands) in our single operating segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months
Ended June 30, |
|
|
For the Six Months
Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue from external customers |
|
$ |
33,432 |
|
|
$ |
37,929 |
|
|
$ |
68,498 |
|
|
$ |
67,944 |
|
Cost of sales (1) |
|
|
(1,062 |
) |
|
|
(1,015 |
) |
|
|
(2,381 |
) |
|
|
(2,270 |
) |
Research and development expenses (2) |
|
|
(29,945 |
) |
|
|
(33,635 |
) |
|
|
(63,961 |
) |
|
|
(69,199 |
) |
Commercial expenses (2) |
|
|
(12,046 |
) |
|
|
(12,180 |
) |
|
|
(23,465 |
) |
|
|
(24,664 |
) |
General and administrative expenses (2) |
|
|
(10,976 |
) |
|
|
(11,702 |
) |
|
|
(23,041 |
) |
|
|
(22,110 |
) |
Other segment expense (3) |
|
|
(46,426 |
) |
|
|
(16,649 |
) |
|
|
(45,065 |
) |
|
|
(10,415 |
) |
Net loss of our single operating segment |
|
$ |
(67,023 |
) |
|
$ |
(37,252 |
) |
|
$ |
(89,415 |
) |
|
$ |
(60,714 |
) |
|
|
(1) Excludes stock-based compensation expense |
|
(2) Excludes stock-based compensation expense and the effects of certain allocations of certain expenses |
|
(3) Includes total other expense, net and income tax provision on the condensed consolidated statements of operations and stock-based compensation expense |
|
|